Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype.
Mar Mallo, Heinz Tuechler, Leonor Arenillas, Sophie Raynaud, Thomas Cluzeau, Lee-Yung Shih, Chiang Tung-Liang, Christina Ganster, Katayoon Shirneshan, Detlef Haase and 10 more
Article in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors at 11 institutions in 8 countries.
Mar MalloMDS Research Group Institut de Recerca Contra la Leucèmia Josep Carreras (IJC) ICO-Hospital Germans Trias i Pujol Universitat Autònoma de Barcelona Badalona Spain.ORCID https://orcid.org/0000-0001-7741-498X
Heinz TuechlerBoltzmann Institute for Leukaemia Research and Hematology Vienna Austria.
Leonor ArenillasHematological Cytology Laboratory Pathology Department Hospital del Mar GRETNHE, IMIM (Hospital del Mar Research Institute) Barcelona Spain.
Sophie RaynaudHematology Department Cote d'Azur University CHU of Nice Nice France.
Thomas CluzeauHematology Department Cote d'Azur University CHU of Nice Nice France.
Lee-Yung ShihDivision of Hematology Chang Gung Memorial Hospital-Linkuo Chang Gung University Taoyuan City Taiwan.
Chiang Tung-LiangDivision of Hematology Chang Gung Memorial Hospital-Linkuo Chang Gung University Taoyuan City Taiwan.
Giovanni MartinelliIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Meldola Italy.
Francesc SoléMDS Research Group Institut de Recerca Contra la Leucèmia Josep Carreras (IJC) ICO-Hospital Germans Trias i Pujol Universitat Autònoma de Barcelona Badalona Spain.
Birmingham Women's Hospital · GBUniversitätsmedizin Göttingen · DECentre Hospitalier Universitaire de Nice · FRChang Gung University · TWHospital Universitari i Politècnic La Fe · ESIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITUniversitat Autònoma de Barcelona · ESHebron University · PSHospital Del Mar · ESHospital Son Llatzer · ESLudwig Boltzmann Institute for Cancer Research · AT
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20-30% with the complementary application of genomic microarrays. We here present a multicenter collaborative study of 163 MDS cases with a normal karyotype (≥10 metaphases) at diagnosis. All cases were analyzed with the ThermoFisher® microarray (either SNP 6.0 or CytoScan HD) for the identification of both copy number alteration(CNA) and regions of homozygosity (ROH). Our series supports that 25 Mb cut-off as having the most prognostic impact, even after adjustment by IPSS-R. This study highlights the importance of microarrays in MDS patients, to detect CNAs and especially to detect acquired ROH which has demonstrated a high prognostic impact.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype. · full record | OpenQuestion